High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients

Hepatology Research

Volumn 40, Issue 10, 2010, Pages 956-962

  Akkarathamrongsin, Srunthron ^a,b   Sugiyama, Masaya ^b   Matsuura, Kentaro ^b   Kurbanov, Fuat ^b   Poovorawan, Yong ^a   Tanaka, Yasuhito ^b   Mizokami, Masashi ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Hepatitis C virus; IL28B; Pegylated interferon plus ribavirin; Single nucleotide polymorphism typing

Indexed keywords

GENOMIC DNA; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA EXTRACTION; FEMALE; GENE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IL28B GENE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 77957245232     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00702.x     Document Type: Article

References (21)

1. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3:41-6.
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-9.
3. Akuta N, Suzuki F, Hirakawa M. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009, 81:452-8.
4. McHutchison JG, Lawitz EJ, Shiffman ML. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-93.
5. Ghany MG, Strader DB, Thomas DL. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-74.
6. Hoofnagle JH, Wahed AS, Brown RS. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis 2009, 199:1112-20.
7. Ge D, Fellay J, Thompson AJ. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
8. Suppiah V, Moldovan M, Ahlenstiel G. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Gen 2009, 41:1100-4.
9. Tanaka Y, Nishida N, Sugiyama M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Gen 2009, 41:1105-9.
10. Thomas DL, Thio CL, Martin MP. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
11. Tanaka Y, Nishida N, Sugiyama M. lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res 2010, 40(5):449-60.
12. Sheppard P, Kindsvogel W, Xu W. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-8.
13. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
14. Marcello T, Grakoui A, Barba-Spaeth G. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-98.
15. Siren J, Pirhonen J, Julkunen I. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 2005, 174:1932-7.
16. Akuta N, Suzuki F, Kawamura Y. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007, 46:403-10.
17. Pereira FA, Pinheiro da Silva NN, Rodart IF. Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol 2008, 80:58-64.
18. Dai CY, Chuang WL, Chang WY. Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006, 193:98-101.
19. Yee LJ, Tang J, Gibson AW. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001, 33:708-12.
20. Constantini PK, Wawrzynowicz-Syczewska M, Clare M. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002, 22:404-12.
21. Rosen HR, McHutchison JG, Conrad AJ. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002, 97:714-20.